您现在的位置: 首页> 研究主题> 重组痘苗病毒

重组痘苗病毒

重组痘苗病毒的相关文献在1985年到2022年内共计145篇,主要集中在基础医学、内科学、畜牧、动物医学、狩猎、蚕、蜂 等领域,其中期刊论文113篇、会议论文5篇、专利文献73338篇;相关期刊46种,包括生物技术通报、生物技术通讯、微生物学杂志等; 相关会议4种,包括中国畜牧兽医学会动物传染病学分会第十二次人兽共患病学术研讨会暨第六届第十四次教学专业委员会会议、2011年中国药学大会暨第11届中国药师周、第九次全国生物制品学术会议等;重组痘苗病毒的相关文献由399位作者贡献,包括金宁一、阮力、邵一鸣等。

重组痘苗病毒—发文量

期刊论文>

论文:113 占比:0.15%

会议论文>

论文:5 占比:0.01%

专利文献>

论文:73338 占比:99.84%

总计:73456篇

重组痘苗病毒—发文趋势图

重组痘苗病毒

-研究学者

  • 金宁一
  • 阮力
  • 邵一鸣
  • 王洪军
  • 刘颖
  • 朱家鸿
  • 朱既明
  • 殷震
  • 毛春生
  • 伊瑶
  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

    • 夏训明(编译)
    • 摘要: 美国FDA于2022年8月9日紧急批准使用JYNNEOS疫苗用于18岁及以上年龄高风险人群预防猴痘感染,使用方法为皮内注射(intradermal injection)。通过这一紧急使用授权令(EUA),美国JYNNEOS疫苗的供应量可较之前增加5倍。该紧急使用授权令同时也批准为18岁以下年龄(儿童及青少年)高风险人群使用JYNNEOS疫苗预防猴痘感染,使用方法为皮下注射(subcutaneous injection)。JYNNEOS疫苗是一种重组痘苗病毒安卡拉株(Modified Vaccinia Ankara,MVA)疫苗。美国FDA于2019年批准JYNNEOS疫苗用于18岁及以上年龄高风险人群用于预防天花和猴痘感染,用法是皮下注射,共需接种两剂次,间隔时间为4周(28天)。JYNNEOS疫苗原来主要是用于免疫功能不全的人群作为替代疫苗预防天花。
    • 张克龙; 曹琛福; 郑敏; 罗廷荣; 金宁一; 李昌; 郝鹏飞; 巫介棚; 朱羿龙; 许汪; 韩继成; 哈卓; 杜寿文; 花群义
    • 摘要: 为了构建并筛选表达16型蓝舌病病毒(BTV-16) VP2蛋白的重组痘苗病毒rVTT-VP2,本研究通过同源重组的方法构建重组痘苗病毒,以TK基因缺失和EGFP绿色荧光为筛选标记,通过噬斑纯化法在BHK-21细胞中纯化10次,并连续传代20次来验证重组痘苗病毒遗传稳定性.PCR鉴定结果显示,VP2基因已整合到重组痘苗病毒基因组中,且未扩增出TK基因.荧光显微镜镜下观察,噬斑处均为表达绿色荧光蛋白的病变细胞.本研究成功构建了表达BTV-16 VP2蛋白重组痘苗病毒rVTT-VP2,为后期疫苗的研究奠定了基础.
    • Dongyue Zhao; Demin Wang; Danfeng Lin
    • 摘要: [目的]Rv3194c基因编码的是结核分枝杆菌的PDZ信号蛋白,本研究探讨该蛋白的亚细胞定位,为其细胞结合蛋白的筛选奠定基础.[方法]从H37Rv基因组中扩增出编码只含有PDZ结构域的tRv3194c (Rv3194c 1-234 aa)的基因片段,在3'端加T2A和EGFP序列,一并插入真核表达载体构建出pcDNA3.1-tRv3194c-T2A-EGFP.将构建好的质粒瞬时转染L929细胞,并共感染重组痘苗病毒vTF7-3,用间接免疫荧光、流式细胞分选以及Western blotting检测融合蛋白的表达以及亚细胞定位.[结果]成功构建出真核表达载体pcDNA3.1-tRy3194c-T2A-EGFP,瞬时转染L929细胞后融合蛋白tRv3194c定位于线粒体膜上,且重组痘苗病毒vTF7-3的感染有助于靶蛋白表达水平的提高.[结论]Rv3194蛋白的PDZ结构域与线粒体外膜相关蛋白结合,为了解该蛋白在细胞内的致病机制提供重要线索.
    • 张会雷; 刘任强; 张敏敏; 王喜军; 葛金英; 温志远; 步志高
    • 摘要: 非洲猪瘟(ASF)是由非洲猪瘟病毒(ASFV)引起的一种猪的传染病,发病率和死亡率几乎达100%,是尚未传入我国的重要的猪烈性病.为研制安全有效的ASF储备疫苗,本研究利用本实验室改造的痘苗病毒(VV),将ASFV的结构蛋白P72和P54或CD2v和P30的基因分别插入到VV基因组中,构建了同时表达P72和P54的重组VV (rVV-P72-P54)以及同时表达CD2v和P30的重组VV (rVV-CD2v-P30).Western blot和间接免疫荧光试验表明外源基因在重组病毒感染的细胞中均能够正确表达.这两株重组病毒在体外细胞培养中的增殖效率与亲本病毒无显著差异.该研究为进一步的动物免疫实验奠定了基础.%African swine fever is a fatal disease of pigs caused by African swine fever virus with morbidity and mortality rates approaching 100 percent,which has not been reported in China as a potent disease of great importance.To develop safe,effective vaccines against ASF,two recombinant vaccinia viruses (VV) were generated based on modified VV,and co-expressed P72 and P54 or co-expressed CD2v and P30.The result of western blot and immunofluorescence assay indicated that the four proteins in recombinant viruses were expressed effectively in infected cells.There was no significant difference between the two recombinant viruses and the original strain in efficiency of virus proliferation and the construction of two recombinant viruses lay the foundation for further study on animal immune experiment.
    • 李猛; 刘畅; 任莉; 郝彦玲; 刘颖; 邵一鸣; 王书晖
    • 摘要: 目的:研究表达HIV-1建立感染相关病毒( T/F)膜蛋白的重组痘苗病毒rTT-B、rTT-C和rTT-CON与gp140蛋白疫苗联合免疫豚鼠后抗体反应情况。方法采取Prime-boost免疫策略对豚鼠进行rTT初免1次,间隔4、8周后gp140蛋白疫苗加强免疫2次。免疫前和末次免疫后2、6、10周采豚鼠血,检测血清中HIV-1特异性结合抗体、中和抗体以及抗体的相对亲和力。结果(1) rTT-B、rTT-C和rTT-CON三种病毒和蛋白联合免疫均诱导了强烈的针对HIV-1 B′/C、B、AE亚型特异性结合抗体,抗体滴度范围为111430~1024000,其中,rTT-C和rTT-CON和蛋白联合免疫2周后诱导的B′/C和AE亚型特异性抗体滴度显著高于rTT-B(P<0.05),但3种病毒蛋白联合免疫诱导的B亚型膜蛋白特异性抗体滴度差异无统计学意义。(2)3种病毒蛋白联合免疫都能诱导较强滴度针对SF162和ZM109的中和抗体,抗体滴度范围为83.76~649.30,3种病毒间差异无统计学意义。(3)3种病毒蛋白联合免疫都能诱导与免疫保护有关的HIV-1 V1V2-gp70特异性抗体,3种病毒间差异无统计学意义。(4)3种病毒蛋白联合免疫诱导的抗体对HIV-1 B′/C、B、AE亚型膜蛋白具有较强亲和力,3种病毒间差异无统计学意义。结论重组痘苗病毒rTT-B、rTT-C和rTT-CON与gp140联合免疫豚鼠后可以有效诱导出针对同源和异源病毒膜蛋白的结合及中和抗体。%Objective To analyze the antibody responses in guinea pigs vaccinated with recombi-nant vaccinia virus( rTT) strains expressing transmitted/founder ( T/F) HIV-1 membrane proteins in combi-nation with gp140 protein.Methods Guinea pigs were primed with rTT strains and boosted twice with gp140 protein in every four weeks.Serum samples were collected from guinea pigs before immunization and in 2, 6 and 10 weeks after the last immunization for the detection of HIV-1-specific binding antibodies, neu-tralizingantibodiesandtherelativeavidityofantibodies.Results (1)Thebindingantibodiesspecificto HIV-1 B′/C, B, AE subtypes were efficiently induced by the immunization of rTT-B, rTT-C and rTT-CON vaccinia strains in combination with gp140 protein.The antibody titers ranged from 111 430 to 1 024 000. More antibodies against HIV-1 B′/C and AE subtypes were induced in guinea pigs by the immunization of rTT-C and rTT-CON strains in combination with gp140 protein than those by using rTT-B strain prime-protein boost strategy (P<0.05).No significant differences with the titers of HIV-1 B subtype specific antibody were observed among the guinea pigs immunized with the three strategies.( 2 ) High titers of SF162 and ZM109 neutralizing antibodies were induced in guinea pigs immunized with rTT-B, rTT-C and rTT-CON vac-cinia strains in combination with gp140 protein, ranging from 83.76 to 649.30.No significant differences were found among the three groups.(3) The HIV-1 V1V2-gp70 specific antibodies associated with protec-tive immunity were induced by immunization of the three virus prime-protein boost strategies.No significant differences were observed among them.(4) Antibodies induced in guinea pigs by immunization of the three strategies showed strong affinity to membrane proteins of HIV-1 B′/C, B, AE subtype strains.No significant differences were found among the three immunization strategies.Conclusion A strong humoral immune re-sponse was induced in guinea pigs primed with recombinant vaccinia virus strains expressing T/F virus HIV-1 membrane proteins and boosted with gp140 protein.
    • 刘芳; 刘莹; 王荣敏; 邵一鸣; 刘颖; 王书晖
    • 摘要: Objective To analyze the mucosal immune responses induced in BALB/c mice after immunization with Vaccinia Tiantan-based HIV vaccine in combination with protein and to evaluate the effi-cacy of different immune strategies and adjuvants.Methods The BALB/c mice were intramuscularly or in-tranasally immunized with the recombinant Vaccinia virus Tiantan strain ( rTV) carrying CN54 Gag-Pol-Env gene and boosted with the gp140 protein and MF59 adjuvant by intramuscular, intranasal or subcutaneous in-jection.Serum, saliva and vaginal lavage samples were collected from the BALB/c mice.The titers of anti-gen specific IgG and IgA were detected by ELISA.Results Significantly enhanced mucosal immune respon-ses were induced by immunization with gp140 protein used in combination with MF59 adjuvant.The IgA an-tibodies elicited in mice mucosal tissues by gp140 protein and MF59 adjuvant were as high as those induced by gp140 protein and cholera toxin subunit B or recombinant flagellin adjuvant.High tiers of gp140-specific IgA antibodies were observed in serum, saliva and vaginal lavage samples from the mice intramuscularly primed with rTV and intranasally boosted with gp140 protein and MF59 adjuvant.The tiers of IgA antibodies in serum and mucosal tissue samples were 1 ∶15 000 and 1 ∶600, respectively.Conclusion High titers of mucosal IgA antibodies were elicited in BALB/c mice intramuscularly primed with Vaccinia Tiantan-based HIV vaccine and intranasally boosted with gp140 protein and MF59 adjuvant, especially in vaginal and oral tissues.This immunization strategy might be able to block the heterosexual transmission of HIV-1 through va-ginal and oral mucosa.%目的:研究痘苗病毒载体HIV疫苗和蛋白疫苗联合运用所激发的黏膜免疫应答,探讨不同途径免疫产生黏膜免疫应答的异同,进一步证实MF59佐剂在激发疫苗黏膜免疫应答方面的效果。方法以表达HIV-1中国流行株 CN54 Gag-Pol-Env 基因的重组痘苗病毒天坛株rTV,重组HIV-1膜蛋白gp140三聚体为抗原,辅以水包油型佐剂( oil-in-water) MF59,在小鼠模型上,通过不同免疫途径组合联合免疫BALB/c小鼠,即重组痘苗病毒初免,免疫途径为滴鼻或肌注,gp140与MF59混合物加强免疫,免疫途径为滴鼻、肌注或皮下,探讨能诱导高效黏膜免疫应答的免疫策略。通过ELISA方法对小鼠血清中HIV-1特异性的IgG和IgA及唾液和阴道分泌物中IgA进行检测。结果MF59是一种良好的黏膜佐剂,能显著增强HIV蛋白疫苗的黏膜免疫应答,所激发的黏膜IgA滴度与鞭毛素蛋白( SF)和霍乱毒素B亚单位( CTB)的黏膜佐剂活性相当;重组痘苗病毒初免(肌注),gp140与MF59加强(滴鼻)联合免疫策略能诱导高水平的血清IgA和黏膜IgA抗体(P<0.05),其抗体滴度分别高达1∶15000和1∶600。结论重组痘苗病毒天坛株rTV系统途径免疫小鼠后蛋白疫苗黏膜途径加强能激发高强度黏膜免疫应答,这一免疫策略及组合可为阻断通过口腔和阴道黏膜传播的艾滋病疫苗研究提供参考。
    • 邓瑶; 孟昕; 张相民; 陈红; 周为民; 王惠娟; 阮力; 谭文杰
    • 摘要: 目的:制备表达绿色荧光蛋白的重组痘苗病毒,并初步探讨其应用。方法:构建制备表达绿色荧光蛋白的重组痘苗病毒RVJ11LacZ-I1LGFP;分别利用药物昔多福韦与抗痘苗病毒高效价免疫血清,建立基于该病毒的荧光生成抑制实验及荧光减数中和实验。结果:荧光生成抑制实验与传统的噬斑生成抑制实验相比,结果一致,但判读更直接快速;重组痘苗病毒RVJ11LacZ-I1LGFP亦可用于体外快速高通量评价正痘病毒疫苗的中和能力。结论:利用表达绿色荧光蛋白的重组痘苗病毒建立了直接简便快速高通量的抗痘病毒药物筛选及体外中和评价技术。%10.3969/j.issn.1009-0002.2012.05.011
    • 刘振江; 鲁会军; 金宁一; 刘昊; 刘燕瑜; 郭欢欢; 凡敏; 岳云强; 陆飞; 秦艳青; 李国江
    • 摘要: 为了构建表达辛德毕斯病毒E基因的重组痘苗病毒,本研究通过基因重组的方法将辛德毕斯病毒E基因及绿色荧光蛋白(enhanced green fluorescent protein,EGFP)基因分别连接至痘苗病毒转移载体pSTK,酶切鉴定得到阳性重组质粒pSTK-SINE-EGFP。采用脂质体转染的方法,将该重组质粒与痘苗病毒天坛株共转染BHK-21细胞,通过同源重组获得重组痘苗病毒。利用EGFP筛选阳性重组痘苗病毒vTTVV-SINE-EGFP,收集感染重组痘苗病毒的BHK-21细胞,SDS-PAGE电泳检测辛德毕斯病毒E基因在细胞中的表达情况,Western blot分析表达产物的免疫原性。结果证明辛德毕斯病毒E基因能在重组痘苗病毒vTTVV-SINE-EGFP中获得表达,且表达产物具有良好的免疫原性。表达辛德毕斯病毒E基因的重组痘苗病毒的成功构建,为研制辛德毕斯病毒活载体疫苗奠定了基础。%To construct recombinant vaccinia virus expressing E gene of Sindbis virus, Sindbis virus E gene and green fluorescent protein (EGFP) gene were inserted to the vaccinia virus transfer vector pSTK by gene recombination. The resulting recombinant plasmid pSTK-SINE-EGFP was confirmed in restriction enzyme digestion. Subsequently, the recombinant plasmid and vaccinia virus Tiantan strain were co-transfected into BHK-21 cells and positive recombinant vaccinia virus was identified by fluorescent plaque purification. Sindbis virus E gene was expressed in BHK-21 cells infected with the recombinant vaccinia virus as determined in SDS-PAGE and Western blot. The results demonstrated that recombinant vaccinia virus expressing Sindbis virus E gene was constructed and expressed product showed good immunogenicity, which laid a solid foundation for development of a live vector vaccine of Sindbis virus.
    • 谭铮; 许金峰; 吴扬; 唐彤宇; 孙淑艳; 王洪军
    • 摘要: 为观察艾滋病病毒结构蛋白与IFNα-2b表达产物诱导机体产生细胞免疫的变化,将编码艾滋病病毒(HIV-1)外膜蛋白env、核心蛋白gag与编码干扰素(IFNα-2b)基因分别插入psFJ16与pSFJ38真核表达载体,利用分子克隆技术构建重组质粒,经脂质体转染与野生型痘病毒在Cos-7细胞内同源重组、筛选、纯化,获得重组痘苗病毒vJ16env/IFNα-2b和vJ38gag/IFNα-2b。免疫小鼠后,检测小鼠周围血与脾淋巴细胞对ConA及LPS的反应性,用流式细胞仪测定小鼠脾细胞CD4+、CD8+细胞计数。结果表明,周围血与脾淋巴细胞对ConA、LPS的反应性,实验组与对照组比较差异有显著性(P〈0.05);CD+T细胞与对照组比较差异有显著性(P〈0.05);CD8+T细胞与对照组比较差异无显著性,但呈增高趋势。结论:重组痘苗病毒能诱导小鼠产生较强的细胞免疫。重组痘苗病毒体外与HIV-1gag阳性血清发生特异性反应,具有免疫原性和免疫反应性。
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号